Abstract
In COVID 19 Pandemic,first line of defence is effective vaccination program.Because of multiple platforms available for vaccine production we tested relative immunogenicity of two vaccines available in India, Covaxin® and Covishield® We performed quantitative analysis of neutralizing antibodies to SARS Cov2 spike (receptor binding domain) protein, from sera of 53 subjects who completed vaccines schedules.There was significantly higher immunogenic response with Covishield® as compared to Covaxin® and are independent of age. Studies on a large scale with long term follow up are needed to further advance the knowledge in this domain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Dr Chanukya Endocrinology clinic,Hyderabad,India
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data that is referred in the manuscript is available.
